| |
| |
|
| Insider
Information: |
Greene Barry E |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
132,162 |
|
|
Indirect Shares
|
6,153,503 |
|
|
| Direct
Value |
$10,599,981 |
|
|
|
Indirect Value
|
$14,044,466 |
|
|
| Total
Shares |
6,285,665 |
|
|
| Total
Value |
$24,644,447 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alnylam Pharmaceuticals Inc |
ALNY |
President |
2020-09-09 |
70,343 |
2020-09-09 |
3,003 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
Director, 10% Owner |
2012-10-10 |
0 |
2012-10-10 |
6,150,500 |
Premium* |
|
|
Karyopharm Therapeutics Inc. |
KPTI |
Director |
2022-08-11 |
13,606 |
2015-04-02 |
0 |
Premium* |
|
|
Acorda Therapeutics Inc |
ACOR |
Director |
2018-05-21 |
1,273 |
2017-01-03 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2022-11-10 |
46,940 |
2021-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
80 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALNY |
Alnylam Pharmaceuticals I... |
COO |
• – – |
2007-10-24 |
4 |
AS |
$30.62 |
$669,359 |
D/D |
(21,700) |
20,351 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
COO |
• – – |
2007-10-24 |
4 |
AS |
$31.36 |
$165,126 |
D/D |
(5,220) |
4,551 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
COO |
• – – |
2007-10-24 |
4 |
AS |
$30.95 |
$329,373 |
D/D |
(10,580) |
9,771 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
COO and Treasurer |
• – – |
2004-08-25 |
4 |
B |
$4.84 |
$6,982 |
D/D |
1,440 |
54,071 |
2.74 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
COO and Treasurer |
• – – |
2004-11-19 |
4 |
B |
$6.00 |
$2,880 |
D/D |
480 |
54,551 |
2.66 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
COO and Treasurer |
• – – |
2006-10-31 |
4 |
AS |
$20.71 |
$258,875 |
D/D |
(12,500) |
42,051 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
COO and TreasurerOfficer |
• – – |
2004-05-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
52,631 |
|
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • • |
2012-10-10 |
4 |
A |
$0.00 |
$0 |
I/I |
6,150,500 |
6,150,500 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2015-04-02 |
4 |
B |
$29.31 |
$87,938 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Director |
– • – |
2017-01-03 |
4 |
AS |
$19.26 |
$58,113 |
D/D |
(3,017) |
0 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Director |
– • – |
2017-01-03 |
4 |
OE |
$15.91 |
$48,000 |
D/D |
3,017 |
3,017 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Director |
– • – |
2017-02-09 |
4 |
AS |
$22.65 |
$16,376 |
D/D |
(723) |
0 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Director |
– • – |
2017-02-09 |
4 |
OE |
$22.13 |
$16,000 |
D/D |
723 |
723 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Director |
– • – |
2017-08-01 |
4 |
AS |
$21.57 |
$215,697 |
D/D |
(10,000) |
0 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Director |
– • – |
2017-08-01 |
4 |
OE |
$18.21 |
$182,100 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Director |
– • – |
2018-05-21 |
4 |
OE |
$20.16 |
$201,600 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Director |
– • – |
2018-05-21 |
4 |
D |
$23.10 |
$201,594 |
D/D |
(8,727) |
1,273 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2020-03-13 |
4 |
OE |
$0.03 |
$100 |
D/D |
3,030 |
6,030 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-08-11 |
4 |
OE |
$1.49 |
$11,250 |
D/D |
7,576 |
13,606 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2016-12-01 |
4 |
AS |
$42.61 |
$1,368,128 |
D/D |
(31,825) |
88,584 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2016-12-01 |
4 |
OE |
$22.75 |
$1,265,014 |
D/D |
55,605 |
120,409 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2017-09-20 |
4 |
AS |
$100.00 |
$7,681,500 |
D/D |
(76,815) |
88,584 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2017-09-20 |
4 |
OE |
$31.39 |
$2,411,223 |
D/D |
76,815 |
165,399 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2017-09-21 |
4 |
OE |
$7.10 |
$146,042 |
D/D |
11,844 |
100,428 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2017-10-02 |
4 |
OE |
$21.35 |
$1,821,497 |
D/D |
85,316 |
185,744 |
0 |
- |
|
80 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
